Catecholamine metabolites and their correlations with biological and clinical features in patients with neuroblastoma

Withdrawn

• Conditions: Neuroblastoma; 10029211

• Registration Number: NL-OMON45532
• Lead Sponsor: Prinses Máxima Centrum voor Kinderoncologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

1. Suspected neuroblastoma patient
2. Urine sample must be available from the moment of diagnosis
3. Histologically proven neuroblastoma

Exclusion Criteria

1. Not neuroblastoma

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Urine and plasma catecholamine metabolites levels<br /><br>- Patient characteristics: age and gender<br /><br>- Tumor characteristics: stage, cytogenetics (such as MYCN amplification, LOH<br /><br>1p, LOH 11q, ALK), MIGB-scan, bone marrow invasion, risk group, MRD<br /><br>-Clinical outcomes (prognosis): primary response to therapy (conform INRG),<br /><br>event-free survival and overall survival</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>